Skip to content
Screener

Opko Health OPK Pharmaceutical — Selling General And Administrative Expense

Other segment segments

Diagnostics
$26.57M-20.4%

Similar metrics at other companies

Gyre Therapeutics, Inc. logo
GYREGyre Pharmaceuticals — Selling General And Administrative Expense
$4.27M+49.3%
Phibro Animal Health logo
PAHCMineral Nutrition — Selling General And Administrative Expense
$1.99M+0.7%
Armstrong World Industries logo
AWIMineral Fiber — Selling General And Administrative Expense
$48.7M+10.7%
Flexible Solutions International logo
FSISelling General And Administrative Expense
$762.36K+0.8%
Helios Technologies logo
HLIOUnallocated Expenses — Selling General And Administrative Expense
$0
Flowers Foods logo
FLOOther Selling Distribution And Administrative Expenses — Selling General And Administrative Expense
$250.56M+5.3%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$1.02B-0.9%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090
(In thousands) / Revenue from services: / PharmaceuticalFor the three months ended June 30, 2026 / —For the three months ended June 30, 2025 / —For the six months ended June 30, 2026 / —For the six months ended June 30, 2025 / —
Corporate
$80,017$49,402$125,774$92,022
Selling, general and administrative:
Pharmaceutical$13,916$13,197$28,121$25,907
Diagnostics26,57433,36952,72571,325
Corporate12,43413,03120,68521,451
$52,924$59,597$101,531$118,683
Research and development:

Item 1. Financial Statements

FAQ

What is Opko Health's pharmaceutical — selling general and administrative expense?
Opko Health (OPK) reported pharmaceutical — selling general and administrative expense of $13.92M in Q2 2026.
How has Opko Health's pharmaceutical — selling general and administrative expense changed year-over-year?
Opko Health's pharmaceutical — selling general and administrative expense increased by 5.4% year-over-year, from $13.2M to $13.92M.
What is the long-term trend for Opko Health's pharmaceutical — selling general and administrative expense?
Over 2 years (2023 to 2025), Opko Health's pharmaceutical — selling general and administrative expense has grown at a -1.6% compound annual growth rate (CAGR), from $55.69M to $53.87M.
What does pharmaceutical — selling general and administrative expense mean?
The operating costs incurred by the pharmaceutical segment for administrative support, marketing, sales, and general corporate overhead. These expenses represent the fixed and variable costs required to support the segment's commercial operations.

Ask your AI about Opko Health's pharmaceutical — selling general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude